Host: Edward J. Mayeaux, Jr., MD, DABFP, FAAFP Guest: Paul P. Doghramji, MD, FAAFP Adherence to CDC vaccination recommendations is a public health issue and a topic of great concern for clinicians. According to the World Health Organization, vaccin

Guest: Monica L. Baskin, PhD Guest: Josep M. Llovet, MD, PhD Hepatocellular carcinoma (HCC) is the most common form of liver cancer. Patients with advanced disease at diagnosis typically are not candidates for potentially curative treatment options

Host: Charles E. Geyer, Jr., MD, FACP Guest: Hope S. Rugo, MD Although outcomes have improved for women with HER2-positive early-stage breast cancer, patients who do not have a pathologic complete response after neoadjuvant therapy are at an increa

Host: Neilanjan Nandi, MD Guest: Russell D. Cohen, MD, FACG, AGAF New and emerging therapeutic targets will add to the existing portfolio of available biologics and small molecule therapies available in IBD. Join Dr. Russel Cohen and Dr. Neil Nandi

Host: Peter Schmid, FRCP, MD, PhD Guest: Javier Cortes, MD, PhD Our understanding of the biology of triple-negative breast cancer (TNBC) is leading to the development of more targeted therapies. Dr. Peter Schmid and Dr. Javier Cortés discuss the ro

Host: Joel L. Cohen, MD Guest: Jason D. Bloom, MD Dr. Joel Cohen and Dr. Jason Bloom discuss the importance of neuromodulator selection and accurate dosing for the glabella and upper face. Dr. Bloom takes us through a patient demonstration of optim

Host: Neilanjan Nandi, MD Guest: Sunanda Kane, MD, MSPH, AGAF Follow Dr. Sunanda Kane and Dr. Neil Nandi as they explore a personalized and proactive treat-to-target strategy to achieve long-term remission in this clinical case scenario of a patien

Host: Adrienne W. Scott, MD Guest: Peter A. Campochiaro, MD Guest: Rahul N. Khurana, MD Retinal vein occlusion (RVO) can lead to macular edema, which is the main cause of vision loss. Accordingly, retina specialists know that time is vision and p

Host: Diana V. Do, MD Guest: Julia Haller, MD Guest: Rishi P. Singh, MD Age-related macular degeneration (AMD) is the most common cause of blindness in adults over the age of 50 years. Anti-VEGF therapy has markedly improved vision outcomes in pa

Host: Diana Shechtman, OD, FAAO Guest: Mark T. Dunbar, OD, FAAO Early diagnosis and early treatment of age-related macular degeneration (AMD) and retinal vein occlusion (RVO) can be critical to preserving a patient’s vision. How can optometrists, w